DEF: Sera Prognostics Announces 2025 Annual Meeting of Stockholders
Proxy Statement
Sera Prognostics will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of its independent auditor.
Summary
- Sera Prognostics will hold its 2025 Annual Meeting of Stockholders online on June 5, 2025, at 9:00 a.m. Mountain Time.
- Stockholders will vote to elect two Class I directors for three-year terms expiring in 2028.
- They will also ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
- The record date for the meeting is April 9, 2025.
- Proxy materials were made available to stockholders on or about April 23, 2025.
- The board recommends voting for the election of Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. as Class I directors and for the ratification of Ernst & Young LLP as the independent auditor.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions, and the recommendations are straightforward.
Positives
- The virtual meeting format is expected to enable greater stockholder attendance and participation, improve meeting efficiency, and reduce costs and environmental impact.
- The board of directors is recommending qualified candidates for election as directors.
- The audit committee is recommending the reappointment of Ernst & Young LLP, indicating satisfaction with their services.
Negatives
- Marcus Wilson, Pharm.D. will not stand for re-election at the 2025 Annual Meeting.
- Ryan Trimble will resign from the board of directors effective June 30, 2025.
Risks
- The classification of the board of directors may have the effect of delaying or preventing changes in control of the company.
- If stockholders do not ratify the appointment of Ernst & Young LLP, the audit committee will reconsider its appointment.
- There is a risk of technical difficulties during the virtual annual meeting.
Future Outlook
The company intends to file final voting results on a Current Report on Form 8-K within four business days after the 2025 Annual Meeting.
Management Comments
- We have determined that the 2025 Annual Meeting will be held in a virtual meeting format only, via the Internet, with no physical in-person meeting because hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our annual meeting.
- We have designed our virtual format to enhance, rather than constrain, stockholder access, participation and communication.
- Our board of directors priority in selecting board members is identification of persons who will further the interests of our stockholders through their established records of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy.
Industry Context
The document reflects standard corporate governance practices for publicly traded companies, including the election of directors, ratification of auditors, and disclosure of related party transactions.
Comparison to Industry Standards
- The board's structure with staggered terms is a common practice among publicly traded companies to ensure continuity and experience.
- The company's commitment to having a majority of independent directors aligns with Nasdaq listing standards and promotes objective oversight.
- The establishment of audit, compensation, and nominating and governance committees is a standard practice to ensure proper oversight of key corporate functions.
- The disclosure of director compensation and related party transactions is in line with SEC regulations and promotes transparency.
- The company's clawback policy is consistent with the requirements of the Dodd-Frank Act and aims to recover incentive compensation in the event of accounting restatements.
- The insider trading policy and prohibition on hedging are common practices to prevent insider trading and maintain investor confidence.
- The company's virtual annual meeting format aligns with the trend of increasing adoption of virtual meetings by publicly traded companies to enhance accessibility and reduce costs.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Marcus Wilson, Pharm.D. | NA | 2025 Annual Meeting | Dr. Wilson will not stand for re-election. |
| Director | Ryan Trimble | NA | June 30, 2025 | Dr. Trimble will resign from the board of directors. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | The board of directors adopted a Clawback Policy to comply with the new SEC clawback rules and Nasdaq listing standards. The Clawback Policy generally provides that we will seek to recover, in the event of a required accounting restatement, excess incentive compensation received by covered officers where that compensation is based on erroneously reported financial information, regardless of fault or misconduct. | October 2, 2023 | The policy is designed to prevent violations of insider trading laws by our personnel and to avoid even the appearance of improper conduct in this regard by our personnel. |
Related Party Transactions
- The company has commercial and laboratory services agreements with Elevance Health.
- Baker Bros. has the right to nominate a director to the board under certain ownership conditions.
- Entities affiliated with Baker Bros. and Chione Ltd. participated in the company's public offering.
- The company has a consulting agreement with Real Endpoints LLC, where Jane F. Barlow, M.D., a member of our board of directors, is Executive Vice President and Chief Clinical Officer.
Stakeholder Impact
- Stockholders have the opportunity to vote on key corporate governance matters.
- The election of directors will shape the leadership and strategic direction of the company.
- The ratification of the auditor ensures the integrity of the company's financial reporting.
- The virtual meeting format aims to enhance accessibility for all stockholders.
- The disclosure of related party transactions promotes transparency and accountability.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will hold the 2025 Annual Meeting of Stockholders on June 5, 2025.
- The company will announce preliminary voting results at the 2025 Annual Meeting and file final results on Form 8-K.
Key Dates
| Date | Description |
|---|---|
| December 2014 | Mansoor Raza Mirza, M.D. has served as a member of our board of directors since December 2014. |
| March 2011 | Ryan Trimble has served as a member of our board of directors since March 2011. |
| January 2011 | Joshua Phillips has served as a member of our board of directors since January 2011. |
| 2010 | Gregory C. Critchfield, M.D., M.S. has served as a member of our board of directors since 2010. |
| November 2011 | Kim Kamdar, Ph.D. has served as a member of our board of directors since November 2011. |
| 2012 | EY has served as our independent registered accounting firm since 2012 |
| November 2021 | Zhenya Lindgardt has served as a member of our board of directors since November 2021 |
| November 10, 2020 | We entered into a laboratory services agreement, dated as of November 10, 2020, with Elevance Health (the Laboratory Services Agreement) relating to our provision of PreTRM tests and related services during the course of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study. |
| February 17, 2021 | We entered into the Commercial Collaboration Agreement, dated as of February 17, 2021, with Elevance Health. |
| February 23, 2021 | We entered into a Fourth Amended and Restated Investors Rights Agreement, dated as of February 23, 2021, or the Investors Rights Agreement, with certain holders of our capital stock. |
| April 2022 | Jane F. Barlow, M.D. has served as a member of our board of directors since April 2022. |
| October 2, 2023 | On October 2, 2023, our board of directors adopted a Clawback Policy to comply with the new SEC clawback rules and Nasdaq listing standards. |
| August 19, 2024 | We entered a consulting agreement, dated as of August 19, 2024, with Real Endpoints LLC (Real Endpoints), pursuant to which Real Endpoints agreed to provide consulting services relating to third-party payer engagement (Statement of Work #1). |
| February 12, 2025 | On February 12, 2025, we closed an underwritten public offering of 1,250,000 shares of Class A common stock, at a public offering price of $4.00 per share, and pre-funded warrants (the Pre-Funded Warrants) to purchase 11,250,000 shares of Class A common stock, at a public offering price of $3.9999 per Pre-Funded Warrant, for gross proceeds of $50.0 million, before deducting underwriting discounts and commissions and offering expenses. |
| February 14, 2025 | On February 14, 2025, we closed on the sale of an additional 1,875,000 shares of Class A common stock pursuant to the underwriters option (on the same terms and conditions as the initial closing) for gross proceeds of an additional $7.5 million, before deducting underwriting discounts and commissions and offering expenses. |
| February 18, 2025 | We subsequently entered into an additional service agreement with Real Endpoints, dated as of February 18, 2025, pursuant to which Real Endpoints agreed to provide services relating to pursuing third-party payer coverage for the PreTRM test in view of the PRIME study results (Statement of Work #2), in the amount of approximately $205,000, subject to certain milestones. |
| March 14, 2025 | On March 14, 2025, Dr. Trimble notified our board of directors of his decision to resign from our board of directors and any committees thereof, effective June 30, 2025. |
| March 17, 2025 | On March 17, 2025, Marcus Wilson, Pharm.D. notified our board of directors of his decision not to stand for re-election to the board of directors at the end of his current term at the 2025 Annual Meeting. |
| March 20, 2025 | Mr. Elliott joined the audit committee on March 20, 2025. |
| April 9, 2025 | The record date for the 2025 Annual Meeting is April 9, 2025. |
| April 23, 2025 | On or about April 23, 2025, we intend to begin sending to our stockholders a Notice of Internet Availability of Proxy Materials (the Notice) containing instructions on how to access our proxy statement for our 2025 Annual Meeting and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the 'Annual Report'). |
| June 5, 2025 | The 2025 Annual Meeting of Stockholders will be conducted solely online via live webcast at www.virtualshareholdermeeting.com/SERA2025 on Thursday, June 5, 2025, at 9:00 a.m. Mountain Time |
| June 30, 2025 | Ryan Trimble will resign from the board of directors effective June 30, 2025. |
| December 24, 2025 | For a stockholder proposal to be considered for inclusion in our proxy statement for our 2026 Annual Meeting of Stockholders (the 2026 Annual Meeting), our Secretary must receive the written proposal at our principal executive offices not later than December 24, 2025. |
| February 5, 2026 | To be timely for our 2026 Annual Meeting, our Secretary must receive the written notice at our principal executive offices:not earlier than February 5, 2026 |
| March 7, 2026 | To be timely for our 2026 Annual Meeting, our Secretary must receive the written notice at our principal executive offices:not later than March 7, 2026. |
Keywords
Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Director Election, Auditor Ratification, Corporate Governance, Sera Prognostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.